Skip to content
10-K

Annual Report

Impact BioMedical, INC. IBO

0001493152-26-009711

← back to feed
Filed
Mar 11, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 6, 2026 107.82M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$1.89M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$2.85M
Cash And Equivalents FY 2025 · Dec 31, 2025 $3K
Cash And Equivalents FY 2025 · Dec 31, 2024 $2M
Stockholders Equity FY 2025 · Dec 31, 2025 $12.61M
Stockholders Equity FY 2025 · Dec 31, 2024 $4.26M
Current Liabilities FY 2025 · Dec 31, 2025 $1.16M
Current Liabilities FY 2025 · Dec 31, 2024 $9.79M
Total Liabilities FY 2025 · Dec 31, 2025 $1.85M
Total Liabilities FY 2025 · Dec 31, 2024 $13.05M
Current Assets FY 2025 · Dec 31, 2025 $411K
Current Assets FY 2025 · Dec 31, 2024 $2.45M
Total Assets FY 2025 · Dec 31, 2025 $17.41M
Total Assets FY 2025 · Dec 31, 2024 $20.29M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.38
Eps Diluted FY 2025 · Dec 31, 2024 −$2.30
Eps Basic FY 2025 · Dec 31, 2025 −$0.38
Eps Basic FY 2025 · Dec 31, 2024 −$2.30
Sga Expense FY 2025 · Dec 31, 2025 $873K
Sga Expense FY 2025 · Dec 31, 2024 $718K
Rd Expense FY 2025 · Dec 31, 2025 $340K
Rd Expense FY 2025 · Dec 31, 2024 $278K
Net Income FY 2025 · Dec 31, 2025 −$11.84M
Net Income FY 2025 · Dec 31, 2024 −$24.71M
Operating Income FY 2025 · Dec 31, 2025 −$4.28M
Operating Income FY 2025 · Dec 31, 2024 −$28.75M
Cost Of Revenue FY 2025 · Dec 31, 2025 $424K
Revenue FY 2025 · Dec 31, 2025 $32K